Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.
暂无分享,去创建一个
J. Blay | O. Mir | A. Italiano | S. Piperno-Neumann | E. Kalbacher | N. Penel | N. Isambert | E. Bompas | F. Duffaud | S. Chabaud | C. Bouvier | C. Chevreau | V. Vidal | A. Thyss | P. Boudou-Rouquette | O. Collard | C. Delcambre | J. Delaye | C. Schiffler | Nicolas De Sousa Carvalho